Comparison of Oxidant and Antioxidant Parameters in Patients with Sjögren’s Syndrome and Healthy Subjects

Abstract Objective Oxidative stress may have an effect on the pathogenesis of diseases, including autoimmune rheumatic diseases. We aimed to investigate the serum paraoxonase activity and other oxidant/antioxidant parameters in patients with Sjögren’s syndrome (SS) and healthy controls. Methods 85 patients with SS and 65 healthy subjects were included in the study. Groups were age and gender-matched and had no liver disease. Serum paraoxonase (PON)-1 activity, stimulated paraoxonase (SPON), PON-1 phenotypes that represent polymorphism (Q192R; QQ, QR, RR), arylesterase (ARE), total oxidant status (TOS), total antioxidant capacity (TAC), oxidative stress index (OSI), advanced oxidative protein products (AOPP), total thioles (TTL) and ischaemia-modified albumin (IMA) were measured in all study participants. Results Statistically significant differences were found in the QQ and QR+RR phenotype of PON-1 for TAC, TOS and TTL (p<0.001) between SS and healthy groups. The other parameters were statistically insignificant. Conclusion Antioxidant parameters were lower in SS patients compared with healthy controls. Conversely, oxidant parameters were higher. This imbalance may play a role in SS pathogenesis. Zusammenfassung Ziel Oxidativer Stress kann die Pathogenese von Krankheiten, einschließlich rheumatischer Autoimmunerkrankungen, beeinflussen. Wir wollten die Paraoxonase-Aktivität im Serum und andere oxidative / antioxidative Parameter bei Patienten mit Sjögren-Syndrom (SS) und gesunden Kontrollpersonen untersuchen. Methode 85 Patienten mit SS und 65 gesunde Probanden wurden in die Studie eingeschlossen. Die Gruppen waren alters- und geschlechtsgleich und hatten keine Lebererkrankungen. Bei allen Studienteilnehmern wurden Serum-Paraoxonase (PON) 1-Aktivität, stimulierte Paraoxonase (SPON), PON 1-Phänotypen, die Polymorphismus darstellen (Q192R; QQ, QR, RR), Arylesterase (ARE), Gesamtoxidationsstatus (TOS), Gesamtantioxidationskapazität (TAC), oxidativer Stress-Index (OSI), fortgeschrittene oxidative Proteinprodukte (AOPP), Gesamtthiole (TTL) und Ischämie-modifiziertes Albumin (IMA) gemessen. Ergebnisse Es gab statistisch signifikante Unterschiede im QQ- und QR+RR-Phänotyp von PON-1 für TAC, TOS und TTL (p<0,001) zwischen SS- und gesunden Gruppen. Die anderen Parameter waren statistisch nicht signifikant. Schlussfolgerung Die Antioxidationsparameter waren bei SS-Patienten im Vergleich zu gesunden Kontrollen niedriger, und umgekehrt waren die Oxidationsparameter höher. Dieses Ungleichgewicht kann eine Rolle bei der SS-Pathogenese spielen.

[1]  K. Tsubota,et al.  Potential Role of Oxidative Stress in Ocular Surface Inflammation and Dry Eye Disease. , 2018, Investigative ophthalmology & visual science.

[2]  M. Whiteman,et al.  Oxidative stress in autoimmune rheumatic diseases , 2018, Free radical biology & medicine.

[3]  M. O’Brien,et al.  Oxidative T Cell Modifications in Lupus and Sjogren’s Syndrome , 2017, Lupus.

[4]  S. Neşelioğlu,et al.  Comparison of serum oxidant and antioxidant parameters in familial Mediterranean fever patients (FMF) with attack free period. , 2014, Acta reumatologica portuguesa.

[5]  A. Tvarijonaviciute,et al.  Serum paraoxonase 1 (PON1) measurement: an update , 2014, BMC Veterinary Research.

[6]  F. Pallardó,et al.  Sjøgren's syndrome-associated oxidative stress and mitochondrial dysfunction: Prospects for chemoprevention trials , 2013, Free radical research.

[7]  G. Paragh,et al.  Decreased human paraoxonase-1 activity in patients with Sjögren's syndrome. , 2010, International immunology.

[8]  A. Vissink,et al.  Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. , 2010, Arthritis and rheumatism.

[9]  A. Kızıltunç,et al.  Evaluation of serum paraoxonase and arylesterase activities in ankylosing spondylitis patients , 2010, Clinics.

[10]  H. Çelik,et al.  Oxidative imbalance in bipolar disorder subtypes: A comparative study , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[11]  F. Akçay,et al.  Serum lipid profile paraoxonase and arylesterase activities in psoriasis , 2009, Cell biochemistry and function.

[12]  S. Erdinç,et al.  Baseline and salt‐stimulated paraoxonase and arylesterase activities in patients with chronic liver disease: relation to disease severity , 2009, Internal medicine journal.

[13]  M. Rabus,et al.  Plasma and tissue oxidative stress index in patients with rheumatic and degenerative heart valve disease. , 2008, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[14]  G. Paragh,et al.  Reduced Paraoxonase1 Activity Is a Risk for Atherosclerosis in Patients with Systemic Lupus Erythematosus , 2007, Annals of the New York Academy of Sciences.

[15]  R. Browne,et al.  Accuracy and biological variation of human serum paraoxonase 1 activity and polymorphism (Q192R) by kinetic enzyme assay. , 2007, Clinical chemistry.

[16]  A. Işık,et al.  Paraoxonase and arylesterase levels in rheumatoid arthritis , 2007, Clinical Rheumatology.

[17]  A. Koçyiğit,et al.  Plasma total antioxidant capacity, lipid peroxidation, and erythrocyte antioxidant enzyme activities in patients with rheumatoid arthritis and osteoarthritis. , 2005, Clinical biochemistry.

[18]  O. Erel,et al.  Measurement of the total antioxidant response in preeclampsia with a novel automated method. , 2005, European journal of obstetrics, gynecology, and reproductive biology.

[19]  S. Karakucuk,et al.  Serum paraoxonase activity is decreased in the active stage of Behçet’s disease , 2004, British Journal of Ophthalmology.

[20]  O. Erel,et al.  A novel automated method to measure total antioxidant response against potent free radical reactions. , 2004, Clinical biochemistry.

[21]  Y. Ikeda,et al.  Serum paraoxonase activity decreases in rheumatoid arthritis. , 2003, Life sciences.

[22]  D. Isenberg,et al.  Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. , 2002, Arthritis and rheumatism.

[23]  R. Jonsson,et al.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group , 2002, Annals of the rheumatic diseases.

[24]  D. Isenberg,et al.  Myositis and swollen knees: disease or treatment complication? , 2002, Annals of the rheumatic diseases.

[25]  L. Bn,et al.  The polymorphic paraoxonase/arylesterase isozymes of human serum. , 1984 .

[26]  B. La Du,et al.  The polymorphic paraoxonase/arylesterase isozymes of human serum. , 1984, Federation proceedings.

[27]  B. La Du,et al.  The human serum paraoxonase/arylesterase polymorphism. , 1983, American journal of human genetics.